Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP-4 in Generalized Anxiety Disorder
NCT00097708Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2004
- Countries
- 1
01
Overview
A Phase 3 trial of 3-(2,3,5-trichloro-phenyl)-pyrazine-2,6-diamine in generalized anxiety disorder (GAD), sponsored by Jazz Pharmaceuticals plc. Started Nov 2004; status: completed.
02
Drugs
3-(2,3,5-trichloro-phenyl)-pyrazine-2,6-diamine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00097708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097708.